The Value of Adjusted PSAD in Prostate Cancer Detection in the Chinese Population

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Oct 17

PMID 39416462

Authors

Fangming Wang

Meng Fu

Yuzhe Tang

Jianxing Li

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the value of adjusted prostate-specific antigen density (PSAD) in the diagnosis of prostate cancer (PCa).

Methods: Data from 410 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed in Beijing Tsinghua Changgung Hospital between November 2014 and March 2024. All patients were divided into PCa and benign prostatic hyperplasia (BPH) groups according to pathological results. Multivariate logistic regression analyses were performed to evaluate the odd ratios (ORs) of predictors for PCa occurrence. Receiver operating characteristic curves were plotted, and the area under the curve (AUC) values were used to assess and compare the diagnostic accuracies of total PSA (tPSA), free-to-total (f/t) PSA, free PSA (fPSA), PSAD, and PSAD (PSAD×weight).

Results: There were 166 patients in the PCa group and 244 in the BPH group. Multivariate analyses demonstrated that PSAD was positively correlated with the presence of PCa, with the highest OR value among all PSA-related parameters (OR = 19.075, <0.001). tPSA, fPSAD, PSAD, and PSAD had high accuracy in predicting PCa, with AUC values of 0.633, 0.730, 0.778, and 0.780. Of note, PSAD had the highest AUC with a sensitivity of 63.3% and specificity of 81.6%. Similarly, in patients with a PSA level in the gray zone, the diagnostic accuracy of PSAD in predicting PCa (AUC, 0.709; 95% CI, 0.616-0.802) remained better than other PSA-related markers.

Conclusion: PSAD has an advantage over other PSA-related markers in detecting PCa and could be used for making biopsy decisions.

References

Cornford P, van den Bergh R, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J . EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024; 86(2):148-163. DOI: 10.1016/j.eururo.2024.03.027. View

Liu J, Wang Z, Li M, Zhou M, Yu Y, Zhan W . Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4-10 ng ml). Asian J Androl. 2019; 22(2):213-216. PMC: 7155794. DOI: 10.4103/aja.aja_46_19. View

Lin Y, Wei X, Uhlman M, Lin X, Wu S, Diao P . PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study. Asian J Androl. 2014; 17(3):503-7. PMC: 4430959. DOI: 10.4103/1008-682X.142129. View

Nordstrom T, Akre O, Aly M, Gronberg H, Eklund M . Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2017; 21(1):57-63. DOI: 10.1038/s41391-017-0024-7. View

Stevens E, Truong M, Bullen J, Ward R, Purysko A, Klein E . Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. Urol Oncol. 2020; 38(11):846.e9-846.e16. DOI: 10.1016/j.urolonc.2020.05.024. View

Teoh J, Yuen S, Tsu J, Wong C, Ho B, Ng A . The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men. Asian J Androl. 2015; 19(1):113-116. PMC: 5227659. DOI: 10.4103/1008-682X.167103. View

Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G . Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019; 6(3):463-478. DOI: 10.1016/j.euf.2019.06.014. View

Washington 3rd S, Baskin A, Ameli N, Nguyen H, Westphalen A, Shinohara K . MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. AJR Am J Roentgenol. 2020; 214(3):574-578. DOI: 10.2214/AJR.19.21559. View

Chen Z, Zhang J, Jin D, Wei X, Qiu F, Wang X . A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score. BMC Cancer. 2023; 23(1):1138. PMC: 10668430. DOI: 10.1186/s12885-023-11306-2. View

10.

Frisbie J, Van Besien A, Lee A, Xu L, Wang S, Choksi A . PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer. Prostate Cancer Prostatic Dis. 2022; 26(2):347-352. DOI: 10.1038/s41391-022-00549-y. View

11.

Choe S, Patel H, Lanzotti N, Okabe Y, Rac G, Shea S . MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection. Urology. 2022; 171:172-178. DOI: 10.1016/j.urology.2022.09.007. View

12.

Zou B, Wen H, Luo H, Luo W, Xie Q, Zhou M . Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer. Ir J Med Sci. 2023; 192(6):2681-2687. PMC: 10692254. DOI: 10.1007/s11845-023-03448-w. View

13.

Zheng X, Xie L, Wang Y, Ding W, Yang K, Shen H . The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol. 2008; 134(11):1207-10. DOI: 10.1007/s00432-008-0400-8. View

14.

Ehdaie B, Vertosick E, Spaliviero M, Giallo-Uvino A, Taur Y, OSullivan M . The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol. 2013; 191(3):660-4. DOI: 10.1016/j.juro.2013.08.088. View

15.

Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh N . The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020; 10(1):20015. PMC: 7672084. DOI: 10.1038/s41598-020-76786-9. View

16.

Song Z, Qian J, Yang Y, Wu H, Wang M, Jiang S . PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium. Asian J Androl. 2020; 23(3):300-305. PMC: 8152427. DOI: 10.4103/aja.aja_61_20. View

17.

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998; 279(19):1542-7. DOI: 10.1001/jama.279.19.1542. View

18.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

19.

Balk S, Ko Y, Bubley G . Biology of prostate-specific antigen. J Clin Oncol. 2003; 21(2):383-91. DOI: 10.1200/JCO.2003.02.083. View

20.

Chen R, Sjoberg D, Huang Y, Xie L, Zhou L, He D . Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts. J Urol. 2016; 197(1):90-96. PMC: 5503119. DOI: 10.1016/j.juro.2016.08.103. View